Considering these results collectively with our conclusion that DUB1 stabilizes TAZ in cancer progression, we propose that targeting DUB1 could block multiple oncogenic pathways and exert synergistic effects in cancer therapy. The gene discussed is WWTR1; the disease is cancer.